Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1481-1500 of 1,743 trials

ALS and TIA: Hyperpolarized Pyruvate MRI Study

We are testing a new MRI method to see if it can help identify metabolic problems in patients with Amyotrophic Lateral Sclerosis and Transient Ischemic Attack. This may improve our understanding of these conditions.

Amyotrophic Lateral Sclerosis (ALS)Transient Ischemic Attack (TIA)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementNeurology

HER2-Expressing Ovarian Cancer: Trastuzumab Deruxtecan with Bevacizumab

We are studying a new combination treatment for patients with HER2-expressing ovarian cancer to see if it works better than standard therapy. The trial will assess safety and how well the treatments help manage the disease.

Ovarian Cancer>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

EPI/HIS Trial: Exploring New Treatment Options

We are investigating a new approach for managing health conditions. This trial aims to understand its effects on patient outcomes.

Healthy Participants>2 yearsSafety phase (I)Internal Medicine

Advanced Non-Small Cell Lung Cancer: MaaT033 and Cemiplimab

We are studying a new treatment combining fecal microbiotherapy with Cemiplimab for patients with advanced NSCLC who have not responded to previous therapies. This trial aims to see if this combination can improve disease control and overall health compared to standard treatments.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Cancer Treatment: NEXTGEN-TIL-ACT Study

We are assessing a new therapy using tumor-infiltrating lymphocytes for cancer patients. The goal is to evaluate how safe and tolerable this treatment is.

Malignant Solid Tumor>2 yearsSafety phase (I)Oncology

CIDP: Riliprubart Treatment Study

We are studying the long-term safety and effectiveness of riliprubart for individuals with chronic inflammatory demyelinating polyneuropathy. This trial will help us understand how well it works in improving disability and strength.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurology

Mucopolysaccharidosis Type IIIA: JR-441 Infusions

We are evaluating the safety and potential effectiveness of JR-441 infusions for patients with mucopolysaccharidosis type IIIA. This study aims to explore how well this treatment works for this rare condition.

Mucopolysaccharidosis III>2 yearsSafety phase (I)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInternal MedicinePediatrics

Brain Injury and Concussion: Tau Tracer Study

We are investigating whether tau levels in the brain are higher in patients with brain injuries and athletes with concussion symptoms. The study also looks at how these brain levels relate to tau found in blood samples.

Cerebral ConcussionIntracerebral HemorrhageTraumatic Brain Injury>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineNeurology

Cervical Dystonia: Botulinum Toxin for Back Muscle Activity

We are studying abnormal muscle activity in the back of people with cervical dystonia. The trial will test whether botulinum toxin injections can help improve this condition and what side effects may occur.

Cervical Dystonia>2 yearsMonitoring phase (IV)Standard MedicinesCost ReimbursementInternal MedicineNeurology

Alzheimer's Disease: Tau and Amyloid Brain Imaging Study

We are investigating how tau protein deposits in the brain can help distinguish between Alzheimer's disease and other conditions. This study may provide insights into early diagnosis and disease progression.

Alzheimer's Disease>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteNeurology

Multiple Myeloma: Isatuximab Combination Therapy

We are studying a new treatment combining isatuximab with other medications for patients with newly diagnosed multiple myeloma who cannot undergo a transplant. The goal is to see how effective and safe this treatment is, and how it impacts patients' lives.

Newly Diagnosed Transplant Ineligible Multiple Myeloma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

ELGN-2112 for Intestinal Malabsorption in Preterm Infants

We are studying whether ELGN-2112 can help preterm infants with intestinal malabsorption achieve full feeding sooner and reduce the risk of serious complications. This trial compares the new treatment to a placebo to assess its safety and effectiveness.

Intestinal Malabsorption>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Heart Procedure: Comparing Blood Thinners

We are studying how two different blood-thinning treatments affect blood clotting in patients undergoing closure of heart defects. This may help us understand which treatment is safer and more effective after the procedure.

Patent Foramen Ovale (PFO) / Atrial Septum Defect (ASD)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Rectal Cancer: Atezolizumab and Bevacizumab After Radiotherapy

We are studying a new treatment for low- to intermediate-risk rectal cancer to see if it helps prevent disease relapse and preserves organ function. The trial also evaluates the safety of this approach.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Refractory Solid Tumors: Propranolol and Vinorelbine Study

We are testing a combination of Propranolol and Vinorelbine in children and teenagers with hard-to-treat solid tumors. The study aims to find the safest dose and evaluate how well this treatment works over time.

Malignant GliomaMalignant Solid TumorDesmoid Tumor>2 yearsSafety phase (I)No PlaceboStandard MedicinesOncologyPediatrics

Advanced Ovarian Cancer: TORL-1-23 Treatment Study

We are studying the effectiveness of TORL-1-23 in women with advanced platinum-resistant ovarian cancer that expresses Claudin 6. This research aims to find new treatment options for this challenging condition.

Peritoneal CancerOvarian CancerFallopian Tube Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Heart Attack Recovery: Ferric Carboxymaltose Treatment

We are studying whether intravenous ferric carboxymaltose can improve survival and quality of life in iron-deficient patients who recently had a heart attack. This trial compares its effects to a placebo treatment.

Recent Heart Attack>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCardiologyInternal Medicine

Multiple Myeloma: Isatuximab Treatment Study

We are studying a new treatment combination for elderly patients with newly diagnosed multiple myeloma who cannot undergo a transplant. The goal is to see if this approach improves disease control and safety compared to standard treatments.

Newly Diagnosed Multiple Myeloma in Elderly Patients>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Crohn's Disease: Cellvizio Imaging Study

We are testing a new imaging technique during surgery for Crohn's disease to help identify healthy tissue margins. This may improve surgical outcomes by ensuring enough healthy tissue is removed.

Crohn's Disease>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

NSTEMI Treatment: Aspirin vs. Aspirin and Fondaparinux

We are comparing the effects of aspirin alone to a combination of aspirin and fondaparinux in patients with NSTEMI. This study aims to see which treatment is more effective and safer before invasive procedures.

Non-ST-Elevation Myocardial Infarction (NSTEMI)>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine